Breaking News

Samsung Biologics, APRINOIA Enter mAb Pact

Samsung will provide cell line development, process development, cGMP manufacturing to IND filing support, for Alzheimer's antibody candidate

Samsung Biologics entered into a contract development and manufacturing agreement with APRINOIA Therapeutics to develop an anti-tau monoclonal antibody candidate to treat primary and secondary tauopathies, including Progressive Supranuclear Palsy and Alzheimer’s disease, which are all currently incurable.

The candidate was selected from APRINOIA’s antibody platform to target specific pathological tau aggregates with novel conformation-dependent epitopes, aiming to slow down disease progression.   

Samsung will provide the full scope of the candidate product’s development phase from cell line development, process development, cGMP manufacturing to IND filing support.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters